FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula 
or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition for treating β-amyloid diseases and synucleinopathies, based on said compound.
EFFECT: obtaining a novel compound and a pharmaceutical composition based thereon, which can be used in medicine to treat such diseases as Alzheimer's disease and Parkinson's disease.
17 cl, 38 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED N-ARYLBENZAMIDES AND RELATED COMPOUNDS FOR TREATING AMYLOID DISEASES AND SYNUCLEINOPATHY | 2005 |
|
RU2381213C2 |
| METHOD OF PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | 2009 |
|
RU2496502C2 |
| COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DISTURBANCES | 2005 |
|
RU2387453C2 |
| ANTI-AMYLOID BETA (A BETA) 1-42 MONOCLONAL ANTIBODIES POSSESSING THERAPEUTIC PROPERTIES | 2006 |
|
RU2551782C2 |
| MONOCLONAL BODY AGAINST AMYLOID BETA | 2008 |
|
RU2571856C2 |
| PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASE | 2012 |
|
RU2618412C2 |
| HUMANISED ANTIBODIES TO β-AMYLOID PEPTIDE | 2008 |
|
RU2475500C2 |
| THERAPEUTIC VACCINE | 2006 |
|
RU2440824C2 |
| 4-(3-((2-ADAMANTYL)AMINO)-3-OXOPROP-1-EN-1-YL)-N-HYDROXYBENZAMIDE - A NEW DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | 2022 |
|
RU2783995C1 |
| COMPOUNDS FOR TREATMENT OF AMYLOIDOSIS | 2009 |
|
RU2491953C2 |
